TOP-5 Price Targets of Analysts on February 13, 2025
Reading Time: 3 minutes
Jazz Pharmaceuticals [IE00B4Q5ZN47]: Bank of America confirms Buy rating with a price target of $182 (34% upside potential) Industry experts see a high probability of success for the antibody Zanidatamab in the first-line GEA study (gastroesophageal adenocarcinoma), referred to as a "transformative catalyst," with results expected in the second quarter of this year. Additionally, the recently achieved IP settlement (intellectual property agreement) for the $1 billion Epidiolex franchise is likely to improve the company's long-term financial metrics....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
